Gene therapy for subtype of retinitis pigmentosa granted orphan status


An RNA-based gene therapy made by Dutch biotech company ProQR Therapeutics has received Orphan Drug Designation from the FDA and European Medicines Agency for treatment of Usher syndrome type II, a form of retinitis pigmentosa.[Read More ] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/gene-therapy-for-subtype-of-retinitis-pigmentosa-granted-orphan-status/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s